AbbVie Inc.
ABBV · NYSE
Next quarter
Expected to report Oct 30, 2026 — estimated from last year’s reporting date.
Consensus is $3.87 EPS for Sep 2026 across 5 estimates, ranging $3.84 to $3.95.
ABBV Jun 2026
- 0.27%
- -2.33%
- $3.64
- $3.65
- —
- $16.99B
Reported results
- $16.99B
- 74.74%
- $6.43B
- 37.86%
- $3.61B
- $2.03
Highlights
- Worldwide net revenue was $16.990 billion, up 10.2% at actual currency rates and 9.5% at constant currency rates from $15.423 billion; reported Q2 net income was $3.61 billion.
- Immunology growth was led by Skyrizi revenue of $5.505 billion, up 24.4%, and Rinvoq revenue of $2.525 billion, up 24.5%; Humira fell 35.9% to $756 million.
- Neuroscience included Vraylar revenue of $1.071 billion, up 18.9%, Botox Therapeutic revenue of $1.042 billion, up 12.2%, and Qulipta revenue of $350 million, up 30.9%.
- Oncology revenue included Venclexta at $771 million, up 11.6%, Elahere at $211 million, up 33.1%, and Epkinly at $103 million, up 46.8%; Imbruvica declined 29.4% to $532 million.
- Six-month revenue was $31.992 billion, up 11.2% reported and 9.9% at constant currency, with operating earnings of $10.4 billion, diluted EPS of $2.42 and operating cash flow of $7.3 billion. No quarterly margin, subscriber or unit count, capex figure, or financial guidance range was supplied.
Analysis
The quarter cannot be judged against consensus because no consensus figures are supplied. AbbVie reported $16.990 billion of revenue, up 10.2% reported and 9.5% at constant currency, versus $15.423 billion a year earlier, while reported Q2 net income was $3.61 billion. Immunology was the clearest engine: Skyrizi rose 24.4% to $5.505 billion and Rinvoq rose 24.5% to $2.525 billion, more than offsetting Humira’s 35.9% decline to $756 million. Neuroscience also contributed, with Vraylar up 18.9%, Qulipta up 30.9% and Vyalev reaching $256 million from $98 million. Oncology growth from Elahere, Epkinly and Venclexta was partly offset by Imbruvica’s 29.4% decline to $532 million. Aesthetics was mixed, with Botox Cosmetic down 2.4% in the quarter to $728 million and Juvederm down to $245 million. Quarterly margins were not provided. Six-month reported growth was 11.2%, versus 10.2% for the quarter.
Guidance
No forward financial guidance ranges were provided in the supplied filing. Management therefore gave no updated revenue, earnings, margin, cash-flow or capital-expenditure outlook against which to compare a prior guide. The company said its pipeline contains approximately 90 compounds, devices or indications, with approximately 60 in mid- and late-stage development, and expects multiple mid-stage programs to move into late-stage development over the next 12 months. It also anticipates several regulatory submissions, approvals and clinical-trial data readouts during that period. The filing includes no quantitative assumptions or caveats for future financial performance.
What drove it
- Skyrizi growth — Worldwide Skyrizi revenue increased 24.4% to $5.505 billion in the quarter.
- Rinvoq growth — Worldwide Rinvoq revenue increased 24.5% to $2.525 billion.
- Neuroscience expansion — Qulipta revenue rose 30.9% to $350 million, while Vyalev revenue increased to $256 million from $98 million.
- Humira erosion — Humira revenue declined 35.9% to $756 million, including a 47.0% decline in the United States.
- Oncology launches — Elahere revenue rose 33.1% to $211 million and Epkinly revenue rose 46.8% to $103 million.
Watch items
- Humira revenue fell 35.9% worldwide and 47.0% in the United States, continuing a material erosion in a former key product.
- Imbruvica revenue declined 29.4% to $532 million, while Other Neuroscience revenue fell 22.7% to $117 million.
- Botox Cosmetic revenue declined 2.4% to $728 million in the quarter, and Botox was selected for government-set Medicare prices beginning in 2028.
- The FDA issued a Complete Response Letter for trenibotulinumtoxinE, requesting additional manufacturing information.
